Improvement of hepatorenal syndrome with extracorporeal albumin dialysis mars: Results of a prospective, randomized, controlled clinical trial

By S. Mitzner, J. Stange, S. Klammt, T. Risler, C. Erley, B. Bader, E. Berger, W. Lauchart, P. Peszynski, Jens Freytag and 7 more. Liver transplantation, 2000

676 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology, Surgery

View Paper: https://www.semanticscholar.org/paper/143b2ea839433804fea7bf54e43834b80dfb38f3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. R. Bellomo
2. John A. Kellum
3. P. Ginés
4. G. Garcia‐Tsao

In Hepatology

1. P. Ginés
2. G. Garcia‐Tsao

In Surgery

1. R. Bellomo
2. P. Ginés
3. John A. Kellum

Citations in the corpus

• Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update (2019, background): “In the most recent meta-analysis and systematic review, no benefit of MARS treatment in reducing mortality as compared to SMT was noted [182].”
• Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014 (2009, neutral): “Various randomized controlled trials in patients with ACLF have shown improvement in hepatic encephalopathy, hepatorenal syndrome, circulatory dysfunction, and immune dysfunction without improvement in transplant-free survival [123–129].”
• Hepatorenal syndrome: the 8th international consensus conference of the Acute Dialysis Quality Initiative (ADQI) Group (2012, background): “Rationale: Extracorporeal support systems in liver disease can be divided into two broad categories: non-cell [96-131] and cell-based systems (Table 7) [132-134].”
• Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases (2021, background): “(195,196) IV albumin improves survival in patients with cirrhosis and SBP. (192) Importantly, patients who most benefited from albumin were those who already had evidence of renal dysfunction (blood urea nitrogen >30 mg/dL or creatinine >1.0 mg/dL) or severe hepatic decompensation (bilirubin >5…”